Further studies which will investigate the contribution of UBE2T and its protein partners to E‐cadherin/β‐catenin post‐translational process and recruitment to plasma membrane in correlation with the regulation of MAPK/ERK could be a promising strategy for unraveling newly molecular therapies against HCC. The gene discussed is UBE2T; the disease is hepatocellular carcinoma.